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Immunogenicity of vaccines hinges upon the 
presence of adjuvants, but few adjuvants are 
currently licensed for human use because of the 
need for more knowledge about how to elicit 
their immunogenic e!ects without toxic side-
e!ects (Mata-Haro et al., 2007; Reed et al., 
2009). T cell activation is promoted by adju-
vants through Toll-like receptors (TLRs) and 
other pattern receptors, which among other 
e!ects trigger DCs to mature and display high 
levels of MHC II molecules and CD86 T cell 
costimulatory proteins (Ishii and Akira, 2007; 
McKee et al., 2007; Steinman and Banchereau, 
2007; Longhi et al., 2009; Reed et al., 2009). 
Increased surface display of MHC II on mature 
DCs results from decreased rates of endocytosis 
and intracellular degradation caused by decreased 
ubiquitination of a critical lysine residue in 
the MHC II-B chain cytoplasmic tail by a ubiq-
uitin ligase, membrane-associated RING-
CH 1 (MARCH1) protein (Cella et al., 1997; 
Villadangos et al., 2001; Shin et al., 2006; 
van Niel et al., 2006; De Gassart et al., 2008; 
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Effective vaccine adjuvants must induce expression of major histocompatability (MHC) 
class II proteins and the costimulatory molecule CD86 on dendritic cells (DCs). However, 
some adjuvants elicit production of cytokines resulting in adverse in!ammatory conse-
quences. Development of agents that selectively increase MHC class II and CD86 expression 
without triggering unwanted cytokine production requires a better understanding of the 
molecular mechanisms in!uencing the production and degradation of MHC class II and 
CD86 in DCs. Here, we investigate how CD83, an immunoglobulin protein expressed on the 
surface of mature DCs, promotes MHC class II and CD86 expression. Using mice with an  
N-ethyl-N-nitrosourea–induced mutation eliminating the transmembrane (TM) region of 
CD83, we found that the TM domain of CD83 enhances MHC class II and CD86 expression 
by blocking MHC class II association with the ubiquitin ligase MARCH1. The TM region of 
CD83 blocks interleukin 10–driven, MARCH1-dependent ubiquitination and degradation of 
MHC class II and CD86 in DCs. Exploiting this posttranslational pathway for boosting MHC 
class II and CD86 expression on DCs may provide an opportunity to enhance the immuno-
genicity of vaccines.
© 2011 Tze et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the !rst six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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no marked di!erence in T cell activation has been found in 
assays using DCs from knockout mice lacking CD83 or from 
an N-ethyl-N-nitrosourea (ENU) mutant mouse strain with 
low CD83 cell surface expression caused by an extended 
C-terminal cytoplasmic tail (Fujimoto et al., 2002; García-
Martinez et al., 2004; Kretschmer et al., 2008; Kuwano et al., 
2007). These Cd83-de#cient mice nevertheless exhibit a 75% 
decrease in positive selection of CD4 T cells in the thymus, 
and a 30–50% decrease in the cell surface expression of MHC II 
and CD86 on DCs, B cells, and thymic epithelium (Fujimoto 
et al., 2002; García-Martinez et al., 2004; Kuwano et al., 2007; 
Kretschmer et al., 2008). The molecular basis for these e!ects 
of CD83 remains unknown (Prazma and Tedder, 2008).
In this study, we identify a posttranslational pathway me-
diated by CD83 that promotes MHC II and CD86 expres-
sion on DCs and opposes the e!ects of IL-10. In this pathway, 
the transmembrane (TM) domain of CD83 inhibits the ac-
tions of MARCH1, a member of a recently discovered family 
of mammalian and viral TM proteins that ubiquitinate and 
down-regulate cell surface MHC, CD86, and other proteins 
(Goto et al., 2003; Bartee et al., 2004; Ohmura-Hoshino et al., 
2006a,b; Matsuki et al., 2007). IL-10 induces MARCH1 
mRNA and causes low MHC II and CD86 expression on 
LPS activated DCs, and the latter e!ects were dependent on 
MARCH1 and opposed by enforced expression of CD83 
TM. These #ndings reveal a pathway by which TLR sig-
naling promotes MHC II and CD86 display on DCs that 
provides opportunities for selectively augmenting vaccine or 
DC immunogenicity.
RESULTS
Mutant mouse strain lacking the CD83 TM region
In a screen of ENU mutagenized mouse pedigrees, we identi-
#ed a strain, anubis, transmitting a Mendelian recessive trait 
characterized by 25% of normal peripheral CD4 cells and a 
high fraction with CD44high activated/memory phenotype 
(Fig. 1 A and Fig S1, A and B). Only 25% of normal CD4+ 
single-positive T cells were present in the thymus of anubis 
(anu, allele name abbreviation) homozygotes, and CD4+CD8+ 
double-positive (DP) thymocytes displayed increased TCRB 
and CD4 on their surface (Fig. 1 B). The latter resembles the 
selective increase in CD4 on DP cells in MHC II–null or 
MHC II mutant thymi, indicating a defect in MHC II signal-
ing to CD4 on DP thymocytes (Cosgrove et al., 1991; Riberdy 
et al., 1998). These defects were not caused by an e!ect of the 
mutation within anubis thymocytes because they developed 
normally in irradiated WT recipients reconstituted with an 
equal mixture of WT (CD229.1) and anu/anu (CD229.1+) 
BM (Fig. S1 C).
The anubis CD4 T cell de#ciency mapped to a 15-Mb 
interval on chromosome 13, excluding the rest of the genome 
(Fig. S1 D). Cd83 lies in the middle of this interval and was 
sequenced because of a similar decrease in CD4 T cells in 
Cd83-de#cient mice (Fujimoto et al., 2002; García-Martinez 
et al., 2004). Genomic DNA sequencing revealed a G-to-T 
substitution in the donor splice site at the boundary between 
Young et al., 2008). Nevertheless, many potent TLR ligands 
cannot be used as adjuvants in humans because they also 
signal the production of cytokines causing fever and adverse 
in"ammatory syndromes. The use of suboptimal adjuvants, 
on the other hand, risks antigen presentation by inadequately 
matured DCs with low MHC II and CD86 that induce T cell 
tolerance (Steinman et al., 2003; Lan et al., 2006). Under-
standing the endogenous pathways that promote mature DC 
expression of MHC II and CD86 may enable more speci#c 
strategies for enhancing vaccine potency.
The problem of ine$cient DC maturation in vaccination 
is compounded by the e!ects of IL-10, which is produced by 
a variety of cells including DCs, macrophages, and Foxp3+ 
regulatory T cells, because this cytokine decreases MHC II 
and CD86 expression on DCs and macrophages (de Waal 
Malefyt et al., 1991; Willems et al., 1994; Redpath et al., 1999). 
IL-10 is an important physiological silencer of excessive im-
mune and in"ammatory responses, and it also interferes with 
e!ective immunity in some infections (Couper et al., 2008). 
This immunosuppressive pathway is exploited by microbes 
that establish lifelong or recurrent infections, exempli#ed by 
Epstein-Barr virus (Hsu et al., 1990), human cytomegalovirus 
(Spencer et al., 2002; Chang et al., 2004; Jenkins et al., 2008), 
equine herpesvirus type 2 (Rode et al., 1993), ovine herpes-
virus 2 (Jayawardane et al., 2008), and the parapoxvirus ORF 
(Chan et al., 2006), which have independently captured a host 
IL-10 gene or cDNA during their evolution. The resulting 
viral IL-10s retain potent suppressive e!ects on monocyte 
and DC MHC II and CD86 expression (de Waal Malefyt 
et al., 1991; Chang et al., 2004; Spencer et al., 2002; Chan 
et al., 2006; Jenkins et al., 2008). Other viruses like murine cyto-
megalovirus (MCMV) do not carry a viral IL-10, but trigger 
infected macrophages or DCs to make endogenous IL-10, 
and thereby achieve suppression of MHC II and CD86 
(Redpath et al., 1999). How IL-10 suppresses surface MHC II 
and CD86 on DCs remains unclear.
DC maturation in response to TLR ligands is also marked 
by induction of CD83, but unlike MHC II and CD86, the 
function of CD83 in T cell activation remains enigmatic 
(Prazma and Tedder, 2008). Like CD86, the CD83 protein 
comprises a single extracellular Ig-like domain, a membrane 
spanning segment, and a cytoplasmic tail. It is most highly ex-
pressed on mature DCs (Zhou et al., 1992), and is induced on 
activated B and T cells (Cramer et al., 2000; Prazma et al., 
2007) by the NF-KB transcription factor (McKinsey et al., 
2000; Lenz et al., 2008). CD83 has been hypothesized to 
function as a T cell costimulatory molecule based upon the 
observation that soluble CD83 extracellular domain fusion 
proteins inhibited T cell activation in vitro and in vivo 
(Lechmann et al., 2001; Zinser et al., 2004; Xu et al., 2007), 
although these results have not been replicated in some stud-
ies (Pashine et al., 2008) and no ligand is currently known. 
Diminished CD83 expression by DCs caused by herpes 
simplex virus type 1 infection or siRNA transfection was ac-
companied by poor stimulation of T cells (Kruse et al., 2000; 
Aerts-Toegaert et al., 2007; Prechtel et al., 2007). In contrast, 
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Figure 1. ENU mouse mutation, anubis, eliminating the CD83 TM segment. (A) Percentage of CD4+ and CD8+ lymphocytes in spleen of individual 
anu/anu or anu/+ mice (dots), with means (columns) and statistical comparison by Student’s t test. Data are representative of three independent experi-
ments. (B) Thymocytes from anu/+ (shaded) or anu/anu mice were stained with antibodies to CD4, CD8, and TCRB. Histograms show CD4 and TCRB on 
CD4+CD8+ (DP) thymocytes. Scatter plots show CD4 and TCRB geometric mean "uorescence intensity (MFI) of DP thymocytes from individual anu/anu or 
anu/+ mice, with means (columns) and statistical comparison by Student’s t test. Data are representative of two independent experiments. (C) Genomic 
DNA sequence traces across the Cd83 exon 4-intron 4 boundary (dashed line). Arrow shows mutated nucleotide. Data are representative from three inde-
pendent samples. (D) cDNA sequences showing the skipped exon 4 in the Cd83anu/anu mutant transcript. Data are representative of three independent 
samples. (E) Amino acid sequence encoded by Cd83anu/anu mRNAs, showing the frameshift and premature stop codons in the mutant protein. (F) Cell sur-
face or total CD83 expression on 6-d GM-CSF cultures of BM-derived CD11c+ DCs from Cd83+/+ and Cd83anu/anu mice, either unstimulated or stimulated 
with 1 µg/ml LPS during the last 16–20 h of culture. Data are representative of two independent experiments, each done using two individual animals.
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Figure 2. CD83 TM segment is necessary and suf"cient to enhance cell surface expression of MHC II and CD86 in DCs. (A) Relative expression 
levels of MHC II or CD86 on ex vivo splenic CD11c+ DCs from individual Cd83+/+ (n = 7) or Cd83anu/anu (n = 8) mice (dots), with means (columns) and sta-
tistical comparison by Student’s t test. Shown are data combined from three independent experiments by using the geometric (geo) MFI of MHC II and 
CD86 of each sample normalized to the mean geo MFI of the Cd83+/+ group within the same experiment (set to 100%). (B) Flow cytometric staining with 
antibodies to MHC II, CD86, and CD83, or with isotype-matched control antibodies on 5-d GM-CSF cultures of BMDCs from Cd83+/+ and Cd83anu/anu mice. 
On day 2 of culture, BMDCs were transduced with retrovirus encoding IRES-GFP (empty) or CD83 $C-IRES-GFP. Histograms show CD11c+GFP+ BMDCs. 
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DCs or BMDCs had lower surface MHC II expression com-
pared with those from Cd83+/+ mice (Fig. 2, A and B, top). 
Expression of CD83 was low for the majority of WT BMDCs, 
which is consistent with the immature phenotype of DCs 
generated in GM-CSF cultures. Transduction of Cd83anu/anu 
BMDCs with GFP vector encoding the mis-spliced Cd83anubis 
lacking the TM segment had no e!ect on MHC II, CD86, or 
MHC I levels (CD83 anubis, Fig. 2 C). In contrast, vector en-
coding full-length CD83 (CD83 WT) increased MHC II and 
CD86 on the majority of GFP+ cells, as did a vector (CD83 
$C) encoding truncated CD83 containing the TM, but lack-
ing the cytoplasmic tail (Fig. 2 B, bottom, and C). Confocal 
microscopy of the transduced BMDCs was unable to detect 
intracellular CD83 anubis protein in the GFP+ cells (Fig S4 A), 
whereas the CD83 $C protein was distributed intracellularly 
and on the plasma membrane in a pattern that colocalized 
with MHC II and CD86 (Fig. S4, B and C). The latter is con-
sistent with published evidence for colocalization of CD83 
with MHC II and CD86 (Klein et al., 2005; Kretschmer et al., 
2008). None of the CD83 constructs signi#cantly a!ected 
surface MHC I expression, indicating the relative speci#city 
of CD83. Likewise, there was no change in CD9 surface ex-
pression on Cd83anu/anu BMDCs or Cd83+/+ or Cd83anu/anu 
BMDCs expressing CD83 $C (Fig S5), despite the associa-
tion between CD9 and MHC II in tetraspanin microdomains 
that promote MHC II–dependent signaling, colocalization of 
MHC II and CD86, and antigen presentation to CD4 T cells 
(Kropshofer et al., 2002; Zilber et al., 2005; Unternaehrer 
et al., 2007). These data indicate that the CD83 TM, but not 
cytoplasmic region, is speci#cally required for normal MHC II 
and CD86 surface expression.
Chimeric constructs were transduced into Cd83anu/anu 
BMDCs to de#ne the minimal CD83 region for normal 
MHC II and CD86 display (Fig. 2 D). MHC II and CD86 
expression were increased on many Cd83anu/anu BMDCs ex-
pressing chimeric proteins with the human CD4 (hCD4) 
extracellular domain and the CD83 TM domain, either with 
or without the CD83 cytoplasmic domain (hCD4 chimera 
1 and 2, respectively). In contrast, expression of the hCD4 
extracellular domain with other TM segments from MHC II 
I-ABb (hCD4 chimera 3) or hCD4 (hCD4 chimera 4) had no 
e!ect. Similarly, the capacity of CD83 to enhance MHC II 
and CD86 was lost if the CD83 TM region was selectively re-
placed by the hCD4 TM segment (Fig. 2 D, CD83 chimera 1). 
The CD83 TM segment therefore represents a minimal func-
tional domain both necessary and su$cient for normal 
MHC II and CD86 display on DCs.
Cd83 exon 4 and intron 4 (Fig. 1 C). Sequencing of Cd83 
cDNA from spleen showed that all detectable mRNA in 
Cd83anu/anu cells was aberrantly spliced from exon 3 to exon 5, 
excluding exon 4 (Fig. 1 D). A frameshift in the translation prod-
uct introduced premature stop codons within exon 5, truncating 
the CD83 protein just upstream of the TM region (Fig. 1 E). The 
loss of cell surface CD83 was con#rmed by "ow cytometric 
staining of LPS-activated GM-CSF–cultured BM-derived 
DCs (BMDCs; Fig. 1 F) or anti-IgM–treated splenic B cells 
(Fig. S2 B), with no appreciable staining above that of an isotype-
speci#c control antibody. Flow cytometric staining of surface 
and intracellular CD83 protein revealed very low levels of intra-
cellular CD83 in Cd83anu/anu BMDCs (Fig. 1 F).
The CD83 TM region stabilizes surface MHC II  
and CD86 display
Analysis of Cd83anu/anu splenic DCs or BMDCs (Fig. 2, A and B) 
and B cells (Fig S2 A) revealed decreased cell surface MHC II 
and CD86, which is also observed in CD83 knockout mice and 
mice with decreased CD83 expression (Fujimoto et al., 2002; 
García-Martinez et al., 2004; Kretschmer et al., 2008; Kuwano 
et al., 2007). This was also seen in Cd83anu/anu B cells cultured 
overnight with or without anti-IgM stimulation (Fig. S2 B). 
In mixed BM chimeras, MHC II and CD86 were also decreased 
on anti-IgM or LPS-activated Cd83anu/anu B cells that developed 
in a Cd83+/+ environment despite normal B cell activation 
based on CD69 or CD25 (Fig. S2 C), indicating that CD83 acts 
cell autonomously to promote MHC II and CD86. Cd83anu/anu 
B cells consistently showed accelerated clearance of antibody-
labeled MHC II and CD86 from the cell surface (Fig S3). This 
#nding contrasts with the absence of any accelerated turnover 
observed in the LCD4.1 mutant cells with low CD83 expres-
sion (Kretschmer et al., 2008), but is consistent with the acceler-
ated MHC II turnover observed in Cd83 knockout B cells 
(Kuwano et al., 2007) and extends this result to CD86. Collec-
tively, these data establish that the TM segment of CD83 is es-
sential to stabilize surface display of MHC II and CD86 by 
regulating their rate of cell surface turnover.
The role of the CD83 TM segment in MHC II and CD86 
surface display was further delineated by expressing CD83 
truncated or chimeric molecules from bi-cistronic retroviral 
vectors together with GFP in GM-CSF cultures of BMDCs 
(Fig. 2). Flow cytometric analysis of GFP+ populations al-
lowed the e!ects of a given vector to be measured indepen-
dently in thousands of single cells with di!erent integration 
sites and expression patterns, with the distribution among the 
cell population visualized as histograms. Cd83anu/anu splenic 
Data are representative of two independent experiments. (C) Schematic of full-length CD83 or variants lacking the TM or cytoplasmic (Cyto) segments 
encoded in bicistronic GFP vectors. Histograms show MHC II, CD86, and MHC I staining of CD11c+GFP+7AAD Cd83anu/anu BMDCs transduced with the 
indicated vectors, overlaid on cells transduced with empty GFP vector. Data are representative of four independent experiments. (D) Schematic of chimeric 
proteins comprising the indicated segments from CD83, human CD4 (hCD4), and mouse MHC class II I-ABb (IAb). Histograms show CD11c+GFP+7AAD 
Cd83anu/anu BMDCs cells analyzed as in C. Data are representative of two independent experiments. (E) CD11c+GFP+ Cd83+/+ or Cd83anu/anu BMDCs trans-
duced with bi-cistronic GFP retroviral vectors encoding IABb WT or IABb K>R were stained with IABb–speci!c antibody. Data are representative of two 
independent experiments.
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expressing MHC II or CD83 (Fig. 4). In B cells doubly trans-
duced with MARCH1:DsRed and I-ABbWT or I-ABbK>R:
GFP, MHC II down-regulation by MARCH1 required the 
MHC II cytoplasmic K225 residue (Fig. 4 A). Likewise, en-
dogenous MHC II and CD86 were expressed on the surface 
of B cells doubly transduced with empty GFP and empty 
DsRed vectors (Fig. 4 B, top, thin line), but both were down-
regulated on cells doubly transduced with empty GFP vector 
and MARCH1:DsRed (Fig. 4 B, top, gray histograms labeled 
“Empty”). Surface expression of MHC II and CD86 was par-
tially restored on cells cotransduced with GFP vector encod-
ing full length CD83 WT, and almost fully restored on most 
cells transduced with CD83 $C lacking the cytoplasmic tail 
(Fig. 4 B, left middle histogram, bold line). In contrast, there 
was no restoration of MHC II or CD86 on MARCH1:
DsRed-expressing cells doubly transduced with CD83 anubis 
lacking the TM segment or CD83 molecules with hCD4 TM 
segments (CD83 chimera 1 and 2, bottom left, bold line). 
CD83 chimeras 1 and 2 were nevertheless expressed on the 
cell surface at higher levels than CD83 WT or CD83 $C 
(unpublished data). Thus the CD83 TM region is the essential 
element antagonizing MARCH1-mediated MHC II and 
CD86 down-regulation, and removal of the cytoplasmic seg-
ment in CD83 $C yields a more potent form of CD83.
These conclusions were reinforced in reciprocal experi-
ments in B cells doubly transduced with MARCH1:DsRed 
and GFP vectors encoding hCD4 chimeras. hCD4 chimera 2 
containing extracellular hCD4 and the TM region of CD83 
partially restored MHC II and CD86 surface display in 
MARCH1-overexpressing cells (Fig. 4 B, right). In contrast, 
hCD4 chimeras 3 and 4 with other TM regions were unable 
to restore MHC II or CD86 (Fig. 4 B, bottom right) despite 
high expression on the cell surface (unpublished data).
CD83 TM inhibits MARCH1 association with MHC II  
and ubiquitination
The #ndings above showed that CD83 TM opposes the e!ects 
of MARCH1 and promotes MHC II surface display, raising 
the possibility that it antagonized MARCH1-MHC II asso-
ciation and ubiquitination. To test this, immunoprecipitation 
and Western blotting experiments were performed in HEK293T 
cells transfected with Flag-tagged hCD4 chimera 3 (Fig. 2 D), 
containing the MHC II I-ABb TM and cytoplasmic regions 
and the hCD4 extracellular domain (Flag-hCD4-IAb), to-
gether with V5-tagged MARCH1. Comparing cells trans-
fected with Flag-hCD4-IAb alone (Fig. 5 A, lane 2) or 
together with MARCH1-V5 (Fig. 5 A, lane 3), anti-ubiquitin 
Western blotting of Flag immunoprecipitates showed that 
ubiquitination of the MHC II chimeric protein (top panels, 
solid arrowheads) was consistently increased in MARCH1 
cotransfected cells and abolished by the K225R (KR) mis-
sense mutation in the Flag-hCD4-IAb cytoplasmic tail (Fig. 5 A, 
lane 4). MARCH1-induced ubiquitination of the FLAG-
hCD4-IAb chimeric protein was also abolished by cotrans-
fecting WT CD83 (Fig. 5, A [lane 5] and B [lane 4]), but was 
una!ected by cotransfecting CD83 chimera 2 where the TM 
CD83 promotes surface display of MHC II and CD86  
in opposition to MARCH1
We next asked if the lower surface MHC II expression on 
DCs in the absence of the CD83 TM segment requires ubiq-
uitination of lysine 225 on the MHC II B chain cytoplasmic 
tail (Ohmura-Hoshino et al., 2006b; Shin et al., 2006). MHC 
II IABb chains with either WT lysine 225 (IABb WT) or a 
K225R mis-sense mutation (IABb K>R) were expressed in 
H2k Cd83+/+ or Cd83anu/anu BMDCs from bi-cistronic GFP 
retroviral vectors (Fig. 2 E). The vector-encoded “b” allotype 
IABb chains were distinguished from endogenous “k” allotype 
IABk chains by staining with IAb allotype-speci#c antibody, 
and GFP+ cells were gated to analyze cells with comparable 
retroviral bi-cistronic mRNA expression. Surface expression 
of IABb WT was signi#cantly lower on Cd83anu/anu BMDCs 
(Fig. 2 E, gray histogram, right) compared with WT BMDCs 
(Fig. 2 E, gray histogram, left), con#rming the requirement for 
the CD83 TM segment in the surface display of WT MHC II. 
In Cd83+/+ BMDCs, expression of IABb K>R (Fig. 2 E, bold 
line, left) was slightly higher than IABb WT (Fig. 2 E, gray 
histogram, left panel), in agreement with previously published 
studies (Ohmura-Hoshino et al., 2006b; Shin et al., 2006). 
Importantly, in Cd83anu/anu BMDCs, the expression of 
I-ABbK>R (bold line, right) restored expression almost to the 
levels of cells with WT CD83. We conclude that the loss of 
the CD83 TM region has little e!ect on surface MHC II dis-
play in the absence of the K225 ubiquitination residue.
In light of the aforementioned results and the recent ob-
servation that MARCH1 and MARCH8 ubiquitin ligases 
diminish surface MHC II and CD86 expression (Goto et al., 
2003; Bartee et al., 2004; Ohmura-Hoshino et al., 2006b; 
Matsuki et al., 2007), we asked if the CD83 TM domain pro-
moted MHC II and CD86 surface display by opposing the 
action of MARCH1 or MARCH8. MARCH1 or MARCH8 
were expressed from bi-cistronic GFP retroviral vectors in 
Cd83+/+ or Cd83anu/anu B cells (Fig. 3, A and B). Because 
MARCH and GFP proteins were encoded in a single, bi- 
cistronic proviral mRNA, GFP levels could be used to infer 
relative expression of MARCH in individual transduced 
splenic B cells. This revealed a dramatic GFP (MARCH) 
dose-dependent decrease in MHC II and CD86 expression 
per cell (Fig. 3 A). Down-regulation of MHC II and CD86 
occurred at a lower threshold of GFP for the MARCH8 vector, 
which may re"ect either increased activity of MARCH8 or 
increased translation from the bicistronic vector. By gating on 
cells expressing low, intermediate or high relative levels of 
MARCH:GFP (Fig. 3 B, top), surface expression of MHC II 
or CD86 was decreased at a lower threshold of GFP(MARCH) 
in Cd83anu/anu B cells (bold lines) compared with Cd83+/+ cells 
(gray histograms). These results establish that the endogenous 
CD83 TM domain opposes the e!ects of MARCH1 and 
MARCH8 to promote surface MHC II and CD86 display.
To cross-titrate CD83 against MARCH1, the latter was 
cloned into a bi-cistronic retroviral expression vector con-
taining a variant Discosoma sp. red "uorescent protein (DsRed) 
so that it could be cotransduced with bi-cistronic GFP vectors 
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the cell surface than WT CD83 (Fig. 5, A and B, far right, 
orange versus green histograms). Flow cytometric measure-
ment of Flag-hCD4-IAb on the surface of the same cells 
showed that WT CD83, but not CD83 chimera 2, inhibited 
segment was substituted with that from hCD4 (Fig. 5, A [lane 6] 
and B [lane 5]). Flow cytometric analysis of the cells used to 
prepare these immunoprecipitates established that CD83 
chimera 2 was nevertheless expressed at higher levels on 
Figure 3. CD83 TM antagonizes MHC II and CD86 down-regulation by MARCH1 and MARCH8 ubiquitin ligases. (A) Cd83+/+ splenic B cells 
activated by LPS were transduced with the empty bi-cistronic GFP vector or GFP vector encoding MARCH1 or MARCH8, and were subjected to "ow cyto-
metric analysis the next day. Cell surface staining for MHC II or CD86 versus GFP "uorescence is shown on gated B220+ cells. Data are representative of 
two independent experiments. (B) Relationship between relative GFP (MARCH1 or MARCH8) expression and surface MHC II or CD86 in splenic B cells from 
Cd83+/+ or Cd83anu/anu mice transduced as in A. Transduced cells were gated into subsets with different levels of GFP (low, intermediate, or high) and sur-
face MHC II or CD86 expression on each subset displayed as overlaid histograms of Cd83+/+ or Cd83anu/anu cells. Data are representative of two indepen-
dent experiments.
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Figure 4. CD83 TM antagonizes MARCH1-mediated MHC II and CD86 down-regulation. (A) LPS-activated Cd83anu/anu splenic B cells were trans-
duced with bi-cistronic GFP vectors encoding IABb WT or IABb K>R in combination with bicistronic DsRed vectors that were either empty or encoding 
MARCH1. Histograms show cell surface IABb gated on B220+GFP+DsRed+ doubly transduced cells (top right gate in plot) expressing empty DsRed vector 
or MARCH1:DsRed vector. Data are representative of two independent experiments. (B) Endogenous MHC II or CD86 expression on B220+GFP+DsRed+ 
Cd83anu/anu B cells coexpressing the indicated GFP and DsRed vectors. Histograms show doubly transduced cells expressing a particular GFP:CD83 or GFP: 
hCD4 chimera (as described in Fig. 2, C and D) and MARCH1:DsRed overlaid with double-transduced cells expressing empty GFP and MARCH1:DsRed vec-
tors. Data are representative of at least two independent experiments.
down-regulation of the MHC II chimeric protein by MARCH1 
cotransfection (Fig. 5, A and B, left), indicating that CD83 
does not require DC- or B cell-speci#c cofactors to block the 
e!ects of MARCH1.
To test if CD83 TM inhibited MHC II ubiquitination 
by blocking association between MARCH1 and MHC II, 
the Flag-hCD4-IAb immunoprecipitates were reblotted for 
MARCH1-V5 (Fig. 5, A and B). Although MARCH1-V5 was 
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Figure 5. CD83 TM inhibits MARCH1 association with MHC II and ubiquitination of MHC II. (A) HEK293T cells were transfected with the indi-
cated vectors encoding Flag-hCD4 IAb WT or KR, March1-V5, CD83 WT, or CD83 chimera 2, where the TM segment is derived from hCD4. Cells were lysed 
and anti-Flag immunoprecipitates were resolved on 12% SDS-PAGE gel, and then analyzed by immunoblotting with anti-ubiquitin, -V5, or -Flag anti-
bodies. Unfractionated NP-40–soluble cell lysates were analyzed in parallel to compare the levels of Flag-hCD4-IAb and MARCH1-V5. The arrows indicate 
ubiquitinated Flag-hCD4 IAb. The asterisk indicates the heavy chain band of the antibody used for immunoprecipitation. Histograms show "ow cytometric 
analysis of cell surface expression of Flag-hCD4-IAb and CD83 on the same samples of transfected cells. (B) Independent replicate experiment of A.  
(C) HEK293T cells were transfected with the indicated vectors encoding MARCH1-V5 and Flag-CD83 WT or CD83 lacking the cytoplasmic tail ($C). Anti-Flag  
immunoprecipitates were resolved on SDS-PAGE gel and analyzed by immunoblotting with anti-V5 to detect MARCH1 associated with Flag-CD83, or with 
anti-FLAG to detect the Flag-CD83 protein itself. Unfractionated cell lysates were analyzed in parallel to compare the levels of MARCH1-V5. The arrows 
indicate the glycosylated form of CD83, the asterisk and double asterisk depict light chain and protein G eluent, respectively. Data shown are representa-
tive of two independent experiments.
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Figure 6. Expression of CD83 $C in DCs blocks MHC II and CD86 down-regulation by IL-10. (A) Cd83+/+ BMDC were transduced with empty bi-
cistronic GFP vector or vector encoding CD83 $C, and then cultured with or without 20 ng/ml IL-10 for 2 d with addition of 1 µg/ml LPS in the last 16–20 h 
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not detected in Flag immunoprecipitates from control cells trans-
fected with MARCH1-V5 alone (Fig. 5, A and B, lane 1) or in 
cells transfected with Flag-hCD4-IAb but not MARCH1-V5 
(Fig. 5, A and B, lane 2), MARCH1-V5 was readily detected 
in Flag immunoprecipitates from cells transfected with both 
(Fig. 5, A and B, lane 3). MARCH1-V5 also precipitated with 
Flag-hCD4-IAb bearing the MHC II K225R (KR) mis-sense 
mutation (lane 4, Fig. 5 A), establishing that ubiquitination of 
the MHC II tail is not required for MARCH1 association. Much 
less MARCH1-V5 immunoprecipitated with Flag-hCD4-IAb 
in cells cotransfected with WT CD83 (Fig. 5, A [lane 5] and B 
[lane 4]), but was una!ected by CD83 chimera 2 bearing 
the hCD4 TM region, despite it being expressed at higher level 
on these cells (Fig. 5, A [lane 6] and B [lane 5]). These results 
establish that CD83 TM inhibits association between MHC II 
and MARCH1.
To test the possibility that CD83 blocked association 
between MHC II and MARCH1 by direct binding to the 
latter, Flag-CD83 immunoprecipitates were tested for presence 
of MARCH1 in HEK293T cells cotransfected with Flag-CD83 
and MARCH1-V5 (Fig. 5 C). Although no MARCH1-V5 
was detected in Flag immunoprecipitates from control cells 
transfected with MARCH1-V5, but not Flag-CD83 (Fig. 5 C, 
lane 1), it was readily detected in Flag-immunoprecipitates 
from cells cotransfected with WT Flag-CD83 (Fig. 5 C, 
lane 2) or Flag-CD83 $C lacking the cytoplasmic tail 
(Fig. 5 C, lane 3).
CD83 inhibits the effect of IL-10 on DC surface MHC II  
and CD86
Because IL-10 has a well established but poorly understood 
e!ect on DCs by decreasing cell surface MHC II and 
CD86 (de Waal Malefyt et al., 1991; Willems et al., 1994; 
Redpath et al., 1999), we asked if this action of IL-10 might 
be inhibited by expression of the potent MARCH1-inhibitor, 
CD83 $C. Cd83+/+ BMDCs were transduced with empty 
bi-cistronic GFP retroviral vector or GFP vector encoding 
CD83 $C, and cultured in the presence or absence of IL-10 
for 2 d with the addition of LPS for the last 16–20 h to in-
duce DC maturation. Flow cytometric staining showed that 
IL-10 dramatically reduced cell surface MHC II and CD86 
on GFP+ DCs expressing the control vector (Fig. 6 A, gray 
histograms). The e!ect of IL-10 was almost completely ne-
gated in GFP+ DCs expressing CD83 $C (Fig. 6 A, bold 
lines). A modest reduction of cell surface CD40 and MHC I 
was also observed in IL-10–treated cells; however, the expres-
sion of CD83 $C had no e!ect on these cell surface proteins 
(Fig. 6 A), lending further support for the speci#city of CD83 
action on MHC II and CD86.
Measurement of March1 mRNA by quantitative PCR in 
these DC cultures demonstrated that IL-10 increased March1 
mRNA by approximately sixfold (Fig. 6 B). To directly ad-
dress if the suppressive e!ect of IL-10 upon surface MHC II 
and CD86 was a result of MARCH1 action, BMDCs from 
March1+/+ or March1/ mice were cultured in the presence 
or absence of IL-10 and LPS as in Fig. 6 A. The addition of 
IL-10 to March1/ BMDCs failed to reduce surface MHC 
II and CD86 expression on these cells (Fig. 6 C, bottom, bold 
lines) as compared with March1+/+ BMDCs (Fig. 6 C, top, 
bold lines). Down-regulation of surface MHC II expression 
by IL-10 was also abolished by mutation of the critical lysine 
225 residue on the MHC II B chain cytoplasmic tail (Fig. 6 D, 
left). The e!ect of the K225R mutation was speci#c to MHC 
II in these cells because surface expression of CD86 was 
down-regulated by IL-10 in a manner identical to cells ex-
pressing WT MHC II (Fig. 6 D, right). These results address a 
longstanding question about how IL-10 down-regulates 
MHC II, by showing that it requires MHC II ubiquitination 
by MARCH1.
Given the requirement for ubiquitination in IL-10 action, 
and the inhibition of ubiquitination by CD83 in MARCH1-
transfected HEK293T cells (Fig. 5), we examined the e!ect of 
CD83 $C expression on endogenous MHC II ubiquitina-
tion in DCs exposed to IL-10. BMDCs were transduced with 
bi-cistronic GFP retroviral vectors encoding either CD83 
anubis or CD83 $C and cultured in the presence of IL-10. After 
3.5 d in IL-10, GFP+ cells were sorted, endogenous MHC II was 
immunoprecipitated, and the immunoprecipitates were ana-
lyzed by Western blot to detect ubiquitin and MHC II (Fig. 6 E). 
Immunoprecipitates from CD83 $C–expressing cells contained 
5.7 times more MHC II than CD83 anubis–expressing 
cells (Fig. 6 E, bottom), but only 1.6 times more ubiquitinated 
of culture. Histograms show cell surface MHC II, CD86, CD40, and MHC I expression on CD11c+GFP+ cells and are representative of three independent 
experiments. (B) RNA and cDNA were prepared from nontransduced Cd83+/+ BMDCs cultured as in A, and quantitative real-time PCR reactions performed 
using March1 and B-actin speci!c primers. March1 expression normalized to B-actin expression is shown by dots for independent cultures, with the 
mean value in LPS-treated samples set to equal 1. Data are representative of two independent experiments. (C) March1+/+ or March1/ BMDCs cultured 
with or without IL-10 with the addition of LPS in the last 16–20 h of culture as in A were stained with antibodies to MHC II and CD86. Histograms shown 
are on CD11c+ cells and are representative of two independent experiments. (D) Cd83+/+ BMDC were transduced with GFP retroviral vectors encoding IABb 
WT or IABb K>R, and then cultured with or without IL-10 and LPS, as in A. Histograms show cell surface MHC II (IABb) and endogenous CD86 on trans-
duced CD11c+GFP+ cells and are representative of two independent experiments. (E) Cd83+/+ BMDCs were transduced with the bi-cistronic GFP vector 
encoding CD83 anubis or CD83 $C, and then cultured in the presence of IL-10. GFP+ cells were sorted and MHC II proteins were immunoprecipitated and 
resolved by SDS-PAGE and analyzed by immunoblotting with antibody to ubiquitin or MHC II I-AB. Arrowhead, position of unmodi!ed MHC II B chain; 
LC, light chain of the antibody used to immunoprecipitate MHC II, providing an internal loading control. Relative intensities of the ubiquitin and MHC II 
bands, and the calculated ratio of ubiquitin to MHC II, are indicated. (F) J774 macrophage cells transduced with either the empty bi-cistronic GFP vector 
or vector encoding CD83 $C, were then left uninfected or infected with MOI of 10 of MCMV 2 d later. Flow cytometric analysis of these cells was done  
4 d after infection. Histograms show MHC II and CD86 on transduced GFP+ cells.
 
 on February 7, 2012
jem
.rupress.org
Downloaded from
 
Published January 10, 2011
160 By blocking MARCH1, CD83 boosts MHC II expression | Tze et al.
ubiquitination of MHC II-B chain tail on lysine 225, result-
ing in the retention of MHC II intracellularly and its sub-
sequent degradation (Ohmura-Hoshino et al., 2006b; Shin 
et al., 2006; Matsuki et al., 2007). Increased mean MHC II 
ubiquitination was suggested in CD83null B cells by Western 
blotting (Kuwano et al., 2007), although because the di!er-
ence did not achieve statistical signi#cance the authors con-
cluded that accelerated MHC II turnover was not caused by 
alterations in ubiquitination.
During DC maturation in the absence of IL-10, our #nd-
ings, together with published data, indicate that two mecha-
nisms cooperate in bringing about decreased MHC II 
ubiquitination and increased surface display (Cella et al., 1997; 
Villadangos et al., 2001; Shin et al., 2006; van Niel et al., 2006; 
De Gassart et al., 2008). First, in the absence of IL-10 there 
is a progressive decrease in expression of March1 mRNA (De 
Gassart et al., 2008; Young et al., 2008). A similar extinction of 
March1 mRNA expression occurs in B cells (Fig S6; Hijikata 
et al., 2007). In parallel, CD83 mRNA and protein is induced 
and opposes the remaining pool of MARCH1 protein. This 
paired mechanism for limiting the action of MARCH1 pre-
sumably explains the display of MHC II and CD86 on CD83 
TM mutant DCs at levels that are approximately half of those 
found on WT mature DCs, and the retention of immuno-
genicity by CD83-de#cient DCs (Fujimoto et al., 2002). In the 
presence of IL-10 and LPS, however, March1 mRNA remains 
high and under these conditions the CD83 TM provides a 
MHC II (Fig. 6 E, top), so that the relative ubiquitination of 
MHC II was decreased to 28% by CD83 $C.
The immunosuppressive e!ect of IL-10 is exploited by 
many microbial pathogens, notably Herpesviridae, to subvert 
host immune responses (Redpath et al., 2001; Slobedman 
et al., 2009). For example, infection by the herpesvirus MCMV 
has been shown to induce IL-10 production by host macro-
phages, which in turn decreased surface MHC II levels on in-
fected cells (Redpath et al., 1999). To test whether or not 
vector-delivered CD83 $C could protect infected macro-
phages from down-regulation of surface MHC II, J774 macro-
phages were transduced with CD83 $C vector or empty vector 
control and infected with MCMV. CD83 $C vector (Fig. 6 F, 
bottom, bold lines), but not empty vector (Fig. 6 F, bottom, 
gray histograms), protected infected cells from losing surface 
MHC II and CD86. This result provides a proof-of-principle 
for future in vivo studies incorporating CD83 $C within 
other viral vaccine antigen delivery vectors.
DISCUSSION
These experiments identify a posttranslational pathway by 
which MHC II and CD86 expression on DCs can be in-
duced both to emulate or augment a key action of TLR- 
ligands and to oppose one of the main immunosuppressive 
e!ects of IL-10 (summarized in Fig. 7). CD83 is induced by 
TLR signals in DCs, and through its TM domain CD83 
inhibits MHC II association with MARCH1, preventing 
MHC II ubiquitination and down-regulation by MARCH1. 
A similar mechanism presumably explains how CD83 TM 
blocks CD86 down-regulation by MARCH1. We show that 
March1 mRNA is induced by the antiin"ammatory cytokine 
IL-10 in DCs, which has also been found in human mono-
cytes (Thibodeau et al., 2008), and show that IL-10 is unable 
to down-regulate surface MHC II or CD86 in March1-
deficient DCs when the lysine 225 residue in MHC II 
B chain cytoplasmic tail is mutated or when endogenous 
MHC II ubiquitination is inhibited by CD83 TM proteins. 
Enforced expression of CD83 TM proteins negates the sup-
pressive e!ect of IL-10 on DC MHC II and CD86 surface 
display and blocks the down-regulation of these proteins on 
MCMV-infected macrophages, which are known to be IL-10 
dependent, leading us to conclude that this key e!ect of 
IL-10 is mediated via its ability to induce March1 mRNA, 
in opposition to the decreased March1 caused by LPS. The 
CD83 pathway for promoting MHC II and CD86 display on 
DCs and opposing the actions of virus-induced IL-10 pro-
vides opportunities to enhance the potency of T cell–directed 
vaccine strategies.
The discovery that CD83 promotes surface display of 
MHC II by opposing its association with MARCH1 and 
ubiquitination provides a mechanistic explanation for the 
accelerated turnover of cell surface MHC II and CD86 mol-
ecules in cells lacking the CD83 TM segment (Fig. S3; 
Kuwano et al., 2007). This result connects the function of 
CD83 with a body of work demonstrating that surface 
MHC II is negatively regulated by MARCH1-dependent 
Figure 7. Summary of CD83 pathway regulating display of MHC II 
and CD86 on DCs. CD83 mRNA is induced by TLR signaling, whereas 
MARCH1 mRNA is induced by IL-10 and diminished by TLR signaling. The 
CD83 TM binds to MARCH1, decreasing MARCH1 association with the TM 
segments of MHC II or CD86 and preventing ubiquitination of lysines in 
their cytoplasmic tails by the MARCH1 RING-CH domain, thereby promot-
ing MHC II or CD86 surface display.
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been shown to induce retention of MHC II molecules in in-
tracellular compartments (Koppelman et al., 1997; Thibodeau 
et al., 2008). The biochemical questions raised by our #ndings 
will be interesting to explore in the future.
The discovery that IL-10 suppression of MHC II and 
CD86 can be negated by the CD83 TM-derivative CD83 $C 
suggests a new strategy for augmenting vaccine potency. 
Delivery of CD83 TM vectors or peptides, either to DCs in 
culture or encoding CD83 $C within viral vaccine antigen 
delivery vectors such as adeno-associated virus or modi#ed 
virus ankara, may provide a way to enhance vaccine potency 
and reverse the e!ects of viral or host IL-10 in the setting of 
chronic infection or cancer. The demonstration here that vector-
encoded CD83 $C can reverse the negative e!ects of MCMV 
infection on display of MHC II and CD86 provides a #rst 
step proof-of-principle toward this longer-term goal.
MATERIALS AND METHODS
Mice. ENU mutagenesis of male C57BL/6 and breeding was done as previ-
ously described (Vinuesa et al., 2005). C57BL/6, CBA, and Rag/ strains 
were originally obtained from The Jackson Laboratory and maintained in our 
speci#c pathogen facility. March1/ mice were as previously described 
(Matsuki et al., 2007). All procedures were done according to the approved 
protocols of the Australian National University Animal Ethics and Experi-
mentation Committee. The anubis strain was maintained on C57BL/6xCBA 
background. Controls used in experiments were either CD83+/+ or CD83anu/+ 
littermates or WT C57BL/6xCBA F2 mice, with matching H-2 genotypes. 
All mice used were generally between 8 and 14 wk old.
Mapping and genotyping. Mapping was done using a set of SNP mark-
ers distinguishing C57BL/6 and CBA alleles, based on validated SNP in-
formation (www.well.ox.ac.uk/mouse/INBREDS). SNP typing was done 
using the Ampli"uor kit (Millipore) according to the manufacturer’s rec-
ommendation. Genotyping was done using SNP ampli"uor assay using the 
following primers: WT allele, 5-GAAGGTCGGAGTCAACGGATTGGT-
GCTTTGACCAGACACTTAC-3; anubis allele, forward, 5-GAAGGT-
GACCAAGTTCATGCTAGGTGCTTTGACCAGACACTTAA-3, and 
reverse, 5-GCAGAAGCTGTGTTGCTCTT-3. All mapping and geno-
typing were done at the Australian Phenomics Facility.
Sequencing. Total RNA was extracted using TRIzol reagent and cDNA 
ampli#ed using Elongase Enzyme Mix (both Invitrogen) according to the 
manufacturer’s recommendations. Sequencing was done using BigDye Ter-
minator v3.1 Cycle Sequencing kit according to the manufacturer’s protocol 
(Applied Biosystems). The following primers were used for sequencing 
(Geneworks): For gDNA sequencing, CD83e4F, 5-GGTAGTCAACAAC-
GCTGCAA-3, and CD83e4R, 5-TGCCTAACCTCACAGGCTCT-3; 
For cDNA sequencing, CD83RNAfor, 5-GCCTCCAGCTCCTGTT-
TCTA-3, CD83RNArev, 5-GAAAGGTTGCCATCTGAGGA-3.
Flow cytometry. Single-cell suspensions were stained with the following 
antibodies: CD83 (Michel-17, eBioscience; or Michel-19, BioLegend), rat 
IgG1 isotype control (eBioscience), human CD4 (S3.4; Invitrogen), or (all 
following antibodies were obtained from BD) I-ABk (10–3.6), IABb (25–9-17), 
IAAk (11–5.2), CD86 (GL1), B220 (RA3-6B2), CD69 (H1.2F3), CD25 
(7D4), CD4 (GK1.5, RM4-5), CD8 (53–6.7), CD44 (IM7), TCRB (H57-
597), MHC I (H-2Kk; 36–7.5), CD11c (HL3), CD229.1 (30C7), CD9 
(KMC8), CD40 (3/23), mouse IgG2a isotype control (G155-178), rat IgG2a 
isotype control (R35-95), and streptavidin-PE and streptavidin-APC. The 
exclusion of dead cells was done by 7-aminoactinomycin-D staining (Invitro-
gen). Intracellular staining was done using the Fixation and Permeabilization 
bu!ers (eBioscience) according to the manufacturer’s instructions. Samples 
potent posttranslational mechanism to promote MHC II and 
CD86 display.
An important focus for future research will be the mecha-
nism by which the CD83 TM segment opposes MARCH1 
association with and ubiquitination of MHC II. In the case of 
viral MIR1 and MIR2 homologues of the MARCH family, 
down-regulation of surface MHC I or CD86 has been shown 
to require two elements: (1) lysines in the substrate cytoplas-
mic tail that are the target of the RING-CH catalytic domain 
in MIR; and (2) TM segments of the substrate and of MIR 
that promote substrate binding (Coscoy and Ganem, 2000; 
Coscoy et al., 2001; Hewitt et al., 2002; Ishido et al., 2000a,b; 
Sanchez et al., 2002; Ohmura-Hoshino et al., 2006a). Speci#c 
association between MARCH8 (cMIR) and chimeric pro-
teins containing TM and cytoplasmic segments of its substrate, 
CD86, has been demonstrated by immunoprecipitation and 
immuno"uorescence (Goto et al., 2003). We show here by 
immunoprecipitation that MARCH1 associates with MHC II 
and CD83. Nevertheless, the antagonistic e!ect of the CD83 
TM cannot be explained by simple competition between 
CD83 and MHC II TM segments for binding to MARCH1, 
because overexpression of hCD4 chimera 3 containing the 
MHC II TM and cytoplasmic domains does not oppose the 
e!ects of MARCH1 on endogenous MHC II or CD86 
(Fig. 4 B). Selective antagonism by CD83 TM and not by 
MHC II TM could be explained by higher a$nity association 
between MARCH1 and CD83 TM compared with MHC II 
TM. Alternatively, CD83 TM may engage MARCH1 at a 
distinct site from MHC II, causing allosteric changes that in-
hibit MARCH1 E3 ligase activity or causing it to redistribute 
to membrane subdomains that are less accessible to MHC II. 
It will also be important to understand how CD83 is itself 
regulated by MARCH1 or other similar proteins, particularly 
because CD83 expression by DCs is diminished by herpes 
simplex virus type 1 infection (Kruse et al., 2000). In unpub-
lished preliminary data on this point, we #nd that enforced 
MARCH1 expression also down-regulates cell surface CD83, 
indicating that MARCH1 may be an inhibitor of its inhibitor, 
CD83, to create a sharp titration between the actions of 
MARCH1 and CD83 in controlling MHC II display. Finally, 
it will be important to determine whether functional inter-
actions between CD83, MARCH1 and MHC II or CD86 
occur on the plasma membrane or in the membranes of in-
tracellular sorting compartments. MHCII, CD86, and CD83 
colocalize on the cell surface and in recycling endosomes of 
B cells and DCs (Klein et al., 2005; Kretschmer et al., 2008). 
Increased endocytosis of surface MHC II has been shown 
to occur during DC maturation and in cells overexpressing 
MARCH8 (Villadangos et al., 2001; Ohmura-Hoshino et al., 
2006b; van Niel et al., 2006). In contrast, Matsuki et al. (2007) 
have shown in MARCH1-de#cient B cells that the rate of 
turnover of cell surface MHC II is decreased, but the rate of 
internalization (presumably into recycling endosomes) is un-
a!ected, indicating that MARCH1 is rate limiting at the level 
of intracellular retention in sorting endosomes. Consistent 
with March1 mRNA induction found here, IL-10 has also 
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AGGACTACAAGGACGACGATGACAAGGGTGGCGGTAAAGTGG-
TGCTGGGCAAAAAAGG-3; Cd4 MA1, 5-CACCACTTTACCGC-
CACCCTTGTCATCGTCGTCCTTGTAGTCCTTTCCCTGAGTG-
GCTGCTGGG-3; March1 CA2, 5-AAAAGTCGACGACTGGTATA-
ACCTCAGG-3.
Retroviral transduction. Supernatant containing retroviruses were har-
vested from transfected Phoenix packaging cell line (a gift from G. Nolan, 
Stanford University, Palo Alto, CA) and used to transduce B cells as described 
(Horikawa and Takatsu, 2006). In brief, murine splenocytes were activated 
overnight with 10 µg/ml LPS (from E. coli 055:B5; Sigma-Aldrich). Cells 
were spinoculated at 2,800 rpm at 29°C for 90 min with retroviral superna-
tant and DOTAP liposomal transfection reagent (Roche), washed, and re-
turned to cultures with 10 µg/ml LPS for another 1–2 d. BMDCs were 
generated and transduced as previously described with some modi#cations 
(Shin et al., 2006). B and T cells, granulocytes, and erythrocytes were re-
moved from BM cell preparations using Ficoll-Paque Plus density gradient 
(GE Healthcare) and standard negative selection method by MACS separa-
tion (Miltenyi Biotec). The remaining cells were cultured in the presence of 
20 ng/ml recombinant mouse GM-CSF (R&D Systems) for 5 d. On day 2 
of culture, cells were spinoculated as described. In some cultures, 20 ng/ml 
recombinant mouse IL-10 (R&D Systems) was added from day 3 onwards, 
with the addition of 1 µg/ml LPS for the last 16–20 h of culture. In some 
experiments, J774 macrophages transduced with retroviral constructs as 
described above were either left uninfected or infected with 10 MOI of 
MCMV-K181-Perth strain 2 d later and analyzed 4 d after infection as previ-
ously described (Andoniou et al., 2005).
Immunoprecipitation and Western blotting. HEK293T cells were 
transfected using PolyFect transfection reagent (QIAGEN) and analyzed by 
"ow cytometric and biochemical assays at 24 h after transfection. To detect 
ubiquitination, MG-132 (Calbiochem) was added at #nal concentration of 
20 µM 2–3 h before cells were harvested. Cells were lysed with TNE bu!er 
(1% Nonidet P-40, 20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1 mM 
sodium orthovanadate, and complete protease inhibitor [Roche]). Flag-tagged 
proteins were immunoprecipitated with anti-Flag M2 antibody (Sigma- 
Aldrich) and protein G–Sepharose (GE Healthcare), and then fractionated by 
12% SDS-PAGE. The membranes were blocked with TBST bu!er (20 mM 
Tris-HCl, pH 7.4, 150 mM NaCl, and 0.05% Triton X-100) and 5% skim 
milk (Difco), and then stained with anti-Flag (M2), anti-V5 (SV5-Pk1;, 
Serotec), or anti-ubiquitin (P4D1; Santa Cruz Biotechnology, Inc.) antibodies, 
followed by detection using mouse IgG TrueBlot (eBioscience). The bands 
were visualized with Western Lightning Chemiluminescence Reagent 
Plus (PerkinElmer).
In some experiments, FACS-sorted GFP+ cells from IL-10–treated, 
BM-derived DCs generated from Cd83+/+ (on H-2b background) mice were 
lysed with lysis bu!er (1% Nonidet P-40, 20 mM TrisHCl, pH 8.0, 150 mM 
NaCl, and 20 mM N-ethylmaleimide) with complete protease inhibitor 
(Roche). MHC class II protein was immunoprecipitated with anti-MHC 
class II antibody (clone: Y-3P; American Type Culture Collection [ATCC]) 
and separated in 10% SDS-PAGE gel. Transferred membrane was stained 
with anti-ubiquitin (clone: P4D1; Santa Cruz Biotechnology, Inc.) or anti–
MHC class II I-A B chain (clone: KL295; ATCC) antibody and detected 
using horseradish peroxidase–conjugated anti–mouse IgG light chain–speci#c 
antibody (Jackson ImmunoResearch Laboratories). Band intensities were 
measured using ImageJ software (Abramo! et al., 2004).
Quantitative real-time RT-PCR. Total RNA was extracted from BMDCs 
using TRIzol (Invitrogen), and cDNA was synthesized using Superscript III re-
verse transcription (Invitrogen). Relative levels of March1 cDNA, as compared 
with the housekeeping gene B-actin, were ascertained using real-time RT-PCR 
and SybrGreen on the ABI 7900 Real-Time PCR system (Applied Biosys-
tems). 7 technical replicates per culture replicate/gene were averaged (mean 
SD = 0.05), and the fold change of the LPS + IL-10 samples compared with the 
LPS only group using the formula 2^($CtLPS only-$CtLPS+IL10). The following 
were collected on a FACSCalibur or LSRII (BD) and data were analyzed 
using FlowJo software (Tree Star, Inc.).
In vitro cell stimulation and endocytosis assay. Splenocytes from mice 
were prepared and cultured as previously described (Jun et al., 2003). Cells 
were unstimulated or stimulated with 10 µg/ml goat anti–mouse IgM F(ab)2 
(Jackson Immunoresearch Laboratories) or 20 µg/ml LPS (from Escherichia 
coli 055:B5; Sigma-Aldrich) in overnight cultures. For endocytosis assay, spleno-
cytes stimulated with 20 µg/ml LPS in overnight cultures were harvested, 
stained with biotinylated-CD86 (GL1; BD) or biotinylated-IABk (10–3.6; BD) 
at 4°C for 30 min, washed twice in media, and returned to 37°C for the indicated 
times. The surface MHC II or CD86 expression that remained after incubation 
time was detected by streptavidin-PE (BD) and analyzed by "ow cytometry.
Vector construction. The full-length sequences for CD83, MHC II (I-ABb), 
March1, and March8 were ampli#ed from C57BL/6 spleen cDNA by Pfx 
DNA polymerase (Invitrogen) and subcloned into pBluescript II SK+ (Strat-
agene). The human CD4 cytoplasmic deletion sequence was ampli#ed from 
pR-IRES-CD4 vector. All site-directed mutants and chimeric receptors 
were generated by PCR-based mutagenesis. The full-length sequences were 
cut and ligated into pcDNA3.1+ (Invitrogen), pMXs-IRES-GFP vector 
(Kitamura et al., 2003; provided by T. Kitamura, University of Tokyo, 
Tokyo, Japan) or pMXs-IRES-DsRed, in which GFP sequence was replaced 
with DsRed sequence from DsRed-Express-C1 (Clontech). The following 
primers (Geneworks; all sequences are listed in 5-3 orientation) were used 
for cloning (restriction enzyme sites are depicted as underline): Cd83 CS1, 
5-TTGGATCCGCCACCATGTCGCAAGGCCTCCAGCTCCTG-3; 
Cd83 CA1, 5-AAAACTCGAGTCATACCGTTTCTGTCTTAGGAAG-3; 
H2-Ab1 CS1, 5-TTGGATCCGCCACCATGGCTCTGCAGATCCCC-
AGCCTC-3; H2-Ab1 CA1, 5-AAAAGTCGACTCACTGCAGGAG-
CCCTGCTGGAGG-3; March1 CS4, 5-TTGGATCCGCCACCAT-
GACCAGCAGCCACATTTGCTG-3; March1 CA1, 5-AAAACTC-
GAGTCAGACTGGTATAACCTCAGGTGG-3; March8 CS1, 5-TTGG-
ATCCGCCACCATGAGCATGCCATTGCACCAGATC-3; March8 
CA1, 5-AAAACTCGAGTCAGACGTTAATAATTTCTGCTCC-3; Cd4 
CS1, 5-TTGGATCCGCCACCATGAACCGGGGAGTCCCTTTTAG-3; 
Cd4 CA1, 5-AAAACTCGAGTCAGTGCCGGCACCTGACACAG-3.
The following primers were used for CD83 mutant $C and MHC 
II I-ABb (H2-Ab1) K253R (restriction enzyme sites or inserted mutations 
are depicted as underline or italic, respectively): Cd83 MA3, 5-AAAA-
CTCGAGTCATTGTAGTCGTGCAAATTTGC-3; H2-Ab1 CA2, 
5-AAAAGTCGACTCACTGCAGGAGCCCTGCTGGAGGAGGGCC-
TCGAGGTCCTCTCTGACTCCTGTGACGGATG-3.
The following primers were used for generating chimeric receptors: 
Cd4 MS2, 5-CAGGTCCTGCTGGAATCCAACATCAAGGTGACAG-
GATGCCCCAAGGAAGC-3; Cd4 MA2, 5-TAGCTTCCTTGGGG-
CATCCTGTCACCTTGATGTTGGATTCCAGCAGGAC-3; Cd4 MS3, 
5-GGTCGACCCCGGTGCAGCCAATGGCAGAAGCTGTGTTGCT-
CTTC-3; Cd4 MA3, 5-GAGAGAAGAGCAACACAGCTTCTGC-
CATTGGCTGCACCGGGGTC-3; Cd4 MS4, 5-AGTCAACTTTCAG-
GAAGTACAGGGCCCTGATTGTGCTGGGGG-3; Cd4 MA4, 5-ACG-
CCCCCCAGCACAATCAGGGCCCTGTACTTCCTGAAAGTTG-3; 
Cd4 MS5, 5-GGCTAGGCATCTTCTTCTGTGTCCGACTACAAA-
GCATTTTCC-3; Cd4 MA5, 5-TATCTGGGAAAATGCTTTGTAG-
TCGGACACAGAAGAAGATGCC-3; Cd4 MS6, 5-GTCGACCCC-
GGTGCAGCCAATGTTGAGCGGCATCGGGGGC-3; Cd4 MA6, 
5-CACGCAGCCCCCGATGCCGCTCAACATTGGCTGCACCGG-
GGTC-3.
The following primers were used for inserting Flag epitope after the 
signal peptide sequence of CD83 and human CD4. V5 epitope was intro-
duced into c-terminus of MARCH1 by ligating with home made pBluescript 
II SK+ V5-tag vector. Cd83 MS1, 5-GGCGATGGACTACAAGGACGAC-
GATGACAAGGGTGGCGGTCGGGAGGTGACGGTGGCTTG-3; Cd83 
MA1, 5-ACCTCCCGACCGCCACCCTTGTCATCGTCGTCCTTG-
TAGTCCATCGCCATCGCGGGTGCC-3; Cd4 MS1, 5-AGGGAA-
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